1. IDDF2018-ABS-0107 Efficacy and safety of TENOFOVIR ALAFENAMIDE (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of TENOFOVIR DISOPROXIL FUMARATE (TDF). (June 2018) Authors: Chan, Henry Lik-Yuen; Buti, Maria; Flisiak, Robert; Ryder, Stephen; Streinu-Cercel, Adrian; Flaherty, John F; Gaggar, Anuj; Mo, Shuyuan; Mani Subramanian, G; Zoulim, Fabrian; Andreone, Pietro; Marcellin, Patrick Journal: Gut Issue: Volume 67(2018)Supplement 2 Page Start: A97 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗